Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Priority to DO2002000523ApriorityCriticalpatent/DOP2002000523A/en
Publication of DOP2002000523ApublicationCriticalpatent/DOP2002000523A/en
239000002587phosphodiesterase IV inhibitorSubstances0.000abstract1
Landscapes
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente invención se refiere a una combinación de un inhibidor selectivo de PDE4 como se define en la presente memoria ; un agonista del receptor B2-adrenérgico, para la administración simultánea, secuencial o por separado por via inhalada en el tratamiento de una enfermedad obstructiva de las vías respiratorias u otra enfermedad inflamatoria.The present invention relates to a combination of a selective PDE4 inhibitor as defined herein; a B2-adrenergic receptor agonist, for simultaneous, sequential or separate administration by inhalation in the treatment of obstructive airways disease or other inflammatory disease.
Compounds derived from substituted pyridazine; hedgehog and smo signaling inhibitors; pharmaceutical composition; and use for the treatment of disorders or syndromes associated with hyperproliferative diseases.
Pharmaceutical composition covered by a film comprising capecitabine and at least one disintegrant, useful in the treatment of cancer for patients who have difficulty swallowing oral solid dosage forms.